Security National Bank of Sioux City Iowa IA Has $2.20 Million Stake in Abbott Laboratories $ABT

Security National Bank of Sioux City Iowa IA grew its position in Abbott Laboratories (NYSE:ABT) by 34.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,246 shares of the healthcare product maker’s stock after purchasing an additional 6,268 shares during the period. Security National Bank of Sioux City Iowa IA’s holdings in Abbott Laboratories were worth $2,200,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Copley Financial Group Inc. lifted its position in shares of Abbott Laboratories by 2.1% in the fourth quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock worth $556,000 after purchasing an additional 93 shares in the last quarter. WealthTrust Axiom LLC grew its position in Abbott Laboratories by 3.2% in the fourth quarter. WealthTrust Axiom LLC now owns 3,064 shares of the healthcare product maker’s stock valued at $384,000 after purchasing an additional 94 shares in the last quarter. Calton & Associates Inc. increased its stake in Abbott Laboratories by 4.4% in the 4th quarter. Calton & Associates Inc. now owns 2,323 shares of the healthcare product maker’s stock valued at $291,000 after buying an additional 97 shares during the last quarter. Private Wealth Asset Management LLC lifted its position in Abbott Laboratories by 0.8% during the 4th quarter. Private Wealth Asset Management LLC now owns 13,055 shares of the healthcare product maker’s stock worth $1,636,000 after buying an additional 100 shares in the last quarter. Finally, Arcadia Investment Management Corp MI boosted its stake in shares of Abbott Laboratories by 3.1% during the 4th quarter. Arcadia Investment Management Corp MI now owns 3,359 shares of the healthcare product maker’s stock worth $421,000 after buying an additional 101 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Performance

ABT traded up $0.12 during trading on Friday, hitting $102.35. The stock had a trading volume of 27,061,539 shares, compared to its average volume of 11,547,542. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The company has a 50 day moving average price of $106.18 and a 200-day moving average price of $99.38. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The firm has a market cap of $177.11 billion, a price-to-earnings ratio of 33.12, a P/E/G ratio of 1.90 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter last year, the firm earned $1.26 earnings per share. The company’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. UBS Group lowered their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Citigroup increased their price target on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Wells Fargo & Company boosted their price target on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Piper Sandler reiterated an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, Bank of America decreased their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

About Abbott Laboratories

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.